Effectiveness of glutamine in the management of oral mucositis in cancer patients: a meta-analysis of randomized controlled trials
- PMID: 33598734
- DOI: 10.1007/s00520-021-06060-9
Effectiveness of glutamine in the management of oral mucositis in cancer patients: a meta-analysis of randomized controlled trials
Erratum in
-
Correction to: Effectiveness of glutamine in the management of oral mucositis in cancer patients: a meta-analysis of randomized controlled trials.Support Care Cancer. 2021 Aug;29(8):4893. doi: 10.1007/s00520-021-06112-0. Support Care Cancer. 2021. PMID: 33983486 No abstract available.
Abstract
Objective: The aim of this meta-analysis was to evaluate the effectiveness of glutamine for preventing or treating moderate-to-severe oral mucositis induced by chemotherapy or radiation therapy in patients with cancer.
Methods: PubMed, Cochrane Library, and Embase were searched for eligible randomized controlled trials (RCTs) up to June 2020. The outcomes analyzed were oral mucositis (at all levels of severity). Data were pooled using the random-effects model and are expressed as risk ratios (RRs) and corresponding 95% confidence intervals (CIs). Heterogeneity was assessed and quantified using I2.
Results: Sixteen RCTs were included in this review. In this meta-analysis, compared with placebo, glutamine significantly reduced the incidence of grade 3 and 4 oral mucositis induced by chemotherapy or radiation therapy (RR, 0.53; 95% CI, 0.32-0.88). In subgroup analysis, oral glutamine administration (RR, 0.56; 95% CI, 0.34-0.92) and a medium or low daily dose of glutamine (RR, 0.58; 95% CI, 0.44-0.77; RR, 0.53; 95% CI, 0.28-0.94; respectively) decreased risk. Glutamine caused a borderline significant reduction in the risk of grade 3 and 4 oral mucositis induced by radiotherapy (RR, 0.75; 95% CI, 0.58-0.99) and especially in its prevention (RR, 0.51; 95% CI, 0.28-0.94).
Conclusions: Glutamine significantly reduces the risk of oral mucositis during chemotherapy or radiation therapy. Furthermore, large prospective trials are required to support these findings.
Keywords: Chemotherapy; Glutamine; Mucositis; Radiation therapy.
Similar articles
-
Role of Glutamine in the Management of Oral Mucositis in Patients with Cancer: A Meta-Analysis of Randomized Controlled Trials.Nutr Cancer. 2022;74(2):482-495. doi: 10.1080/01635581.2021.1889623. Epub 2021 Feb 19. Nutr Cancer. 2022. PMID: 33605813
-
Glutamine in Alleviation of Radiation-Induced Severe Oral Mucositis: A Meta-Analysis.Nutr Cancer. 2016 Jul;68(5):734-42. doi: 10.1080/01635581.2016.1159700. Epub 2016 Apr 4. Nutr Cancer. 2016. PMID: 27045857 Review.
-
Oral Glutamine May Have No Clinical Benefits to Prevent Radiation-Induced Oral Mucositis in Adult Patients With Head and Neck Cancer: A Meta-Analysis of Randomized Controlled Trials.Front Nutr. 2020 Apr 17;7:49. doi: 10.3389/fnut.2020.00049. eCollection 2020. Front Nutr. 2020. PMID: 32363198 Free PMC article.
-
Effects of oral supplementation in the management of oral mucositis in cancer patients: A meta-analysis of randomized clinical trials.J Oral Pathol Med. 2020 Feb;49(2):117-125. doi: 10.1111/jop.12901. Epub 2019 Jun 25. J Oral Pathol Med. 2020. PMID: 31172573 Review.
-
Efficacy of probiotics in the treatment of oral mucositis in head and neck cancer patients: A systematic review and meta-analysis.Microb Pathog. 2024 Aug;193:106785. doi: 10.1016/j.micpath.2024.106785. Epub 2024 Jul 4. Microb Pathog. 2024. PMID: 38971507
Cited by
-
Targeting the Metabolic Paradigms in Cancer and Diabetes.Biomedicines. 2024 Jan 17;12(1):211. doi: 10.3390/biomedicines12010211. Biomedicines. 2024. PMID: 38255314 Free PMC article. Review.
-
Glutamine Supplementation as an Anticancer Strategy: A Potential Therapeutic Alternative to the Convention.Cancers (Basel). 2024 Mar 5;16(5):1057. doi: 10.3390/cancers16051057. Cancers (Basel). 2024. PMID: 38473414 Free PMC article. Review.
-
Use of oral glutamine in radiation-induced adverse effects in patients with thoracic and upper aerodigestive malignancies: Results of a prospective observational study.Oncol Lett. 2022 Jan;23(1):19. doi: 10.3892/ol.2021.13137. Epub 2021 Nov 16. Oncol Lett. 2022. PMID: 34858523 Free PMC article.
-
Methylene blue for intractable pain from oral mucositis related to cancer treatment: a randomized phase 2 clinical trial.BMC Med. 2022 Nov 3;20(1):377. doi: 10.1186/s12916-022-02579-8. BMC Med. 2022. PMID: 36324139 Free PMC article. Clinical Trial.
-
Effects of various treatments for preventing oral mucositis in cancer patients: A network meta-analysis.PLoS One. 2022 Dec 8;17(12):e0278102. doi: 10.1371/journal.pone.0278102. eCollection 2022. PLoS One. 2022. PMID: 36480513 Free PMC article.
References
-
- Forastiere AA, Trotti A (1999) Radiotherapy and concurrent chemotherapy: a strategy that improves locoregional control and survival in oropharyngeal cancer. J Natl Cancer Inst 91(24):2065–2066 - DOI
-
- Seiwert TY, Cohen EE (2005) State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 92(8):1341–1348 - DOI
-
- Sonis ST, Elting LS, Keefe DM et al (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(9 Suppl):1995–2025 - DOI
-
- Merlano M, Marchetti G (2003) Radiochemotherapy in head and neck cancer. Cancer Treat Rev 29:291–296 - DOI
-
- Brizel D, Albers M, Fischer S et al (1998) Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798–1804 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical